secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001437749-24-015083
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q1 net loss $10.1M; FDA clears percutaneous electrode; plans $60M rights offering
--------------------------------------------------------------------------------

- FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for soft tissue ablation in percutaneous and intraoperative procedures.
- CellFX nsPFA Cardiac Clamp 510(k) process ongoing; FDA requests clinical data; feasibility study submitted in Netherlands.
- Board approved rights offering of up to $60M in units; record date moved to mid-June; fully subscribed adds $66M warrants.
- GAAP net loss Q1 2024 $10.1M vs $9.8M year ago; cash $34.9M (down from $44.4M Dec 31, 2023).
- Non-GAAP net loss $8.1M vs $8.6M prior year; Q1 cash used $9.5M including $2M annual bonus payouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/0001437749-24-015083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924015083/plse20240321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer